ixazomib citrate - Profile

What are the generic drug sources for ixazomib citrate and what is the scope of patent protection?

Ixazomib citrate is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ixazomib citrate has one hundred and eighty-seven patent family members in forty-four countries.

Summary for ixazomib citrate

International Patents:	187
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ixazomib citrate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ixazomib citrate

Constraining patent/regulatory exclusivity:

8,859,504

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for IXAZOMIB CITRATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NINLARO	Capsules	ixazomib citrate	2.3 mg, 3 mg and 4 mg	208462	1	2019-11-20

US Patents and Regulatory Information for ixazomib citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No	8,871,745
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No	9,175,017
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No	8,003,819		Y	Y
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No	7,442,830		Y	Y
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No	8,530,694		Y	Y
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No	8,859,504		Y	Y
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No	7,687,662		Y	Y

Expired US Patents for ixazomib citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-003	Nov 20, 2015	9,233,115
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015	8,546,608
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-002	Nov 20, 2015	9,233,115
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-003	Nov 20, 2015	8,546,608
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-002	Nov 20, 2015	8,546,608
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015	9,233,115

International Patents for ixazomib citrate

Country	Patent Number	Title	Estimated Expiration
Argentina	067824	COMPUESTOS DE ACIDO BORONICO Y ESTER BORONICO INHIBIDORES DE LA PROTEASOMA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USOS DE LOS MISMOS PARA EL TRATAMIENTO DEL CANCER.
Australia	2007357338	Proteasome inhibitors
Brazil	PI0721905	INIBIDORES DE PROTEASSOMA
Canada	2695082	INHIBITEURS DE PROTEASOMES (PROTEASOME INHIBITORS)
Chile	2008002159	Compuestos derivados de n-(((1r, 4r)-4-aminociclohexil)metil) sulfonaminas sustituidas con heterociclos, antagonistas del receptor npy y5; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar anorexia y obesidad.
China	101772507	Proteasome inhibitors
China	102961387	Proteasome inhibitor

Supplementary Protection Certificates for ixazomib citrate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2178888	1790016-8	Sweden		PRODUCT NAME: IXAZOMIB AND PHARMACEUTICALLY ACCEPTABLE SALTS AND ESTERS THEREOF, SUCH AS IXAZOMIB CITRATE; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/16/1094, 2016-11-23; DEN 19 JUNI 2025 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 1790034-1 1490061-7 1790019-2 2090047-8 2390009-5 2390012-9 2090033-8 1790016-8 2190015-4 1990020-8 1090038-9 1190029-7 SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. DEN BESLUTADE SKYDDSTIDEN FOER RESPEKTIVE TILLAEGGSSKYDD FRAMGAR AV SVENSK PATENTDATABAS.
2178888	122017000025	Germany		PRODUCT NAME: LXAZOMIB UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE UND ESTER WIE LXAZOMIBCITRAT; REGISTRATION NO/DATE: EU/1/16/1094 20161121
2178888	300871	Netherlands		PRODUCT NAME: IXAZOMIB EN FARMACEUTISCH AANVAARDBARE ZOUTEN EN ESTERS DAARVAN, ZOALS IXAZOMIBCITRAAT; REGISTRATION NO/DATE: EU/1/16/1094 20161123
2178888	17/2017	Austria		PRODUCT NAME: IXAZOMIB UND PHARMAZEUTISCH ANNEHMBARE SALZE UND ESTER DAVON, WIE AUCH IXAZOMIB-CITRAT; REGISTRATION NO/DATE: EU/1/16/1094/ 001-003 (MITTEILUNG) 20161123
2178888	LUC00013	Luxembourg		PRODUCT NAME: IXAZOMIB ET SELS ET ESTERS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI, TEL QUE LE CITRATE D'IXAZOMIB; AUTHORISATION NUMBER AND DATE: EU/1/16/&1094 20161123
2178888	17C1011	France		PRODUCT NAME: IXAZOMIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET SES ESTERS TELS QUE LE CITRATE D'IXAZOMIB; REGISTRATION NO/DATE: EU/1/16/1094 20161123
2178888	C20170014 00227	Estonia		PRODUCT NAME: IKSASOMIIB;REG NO/DATE: EU/1/16/1094 23.11.2016

Investment Scenario, Market Dynamics, and Financial Trajectory for Ixazomib Citrate

Last updated: February 3, 2026

Summary

This report provides a comprehensive analysis of ixazomib citrate within the pharmaceutical landscape, focusing on its market potential, competitive positioning, and financial outlook. As an oral proteasome inhibitor approved for multiple myeloma, ixazomib citrate's growth prospects are influenced by evolving treatment paradigms, regulatory pathways, and competitive dynamics. The analysis includes current market size, growth drivers, potential challenges, and projections over the next five years, enabling investors and stakeholders to make informed decisions.

---

What is Ixazomib Citrate?

• Generic Name: Ixazomib citrate
• Mechanism of Action: Oral proteasome inhibitor targeting the 26S proteasome, inducing apoptosis of malignant plasma cells.
• Approved Indications: Multiple myeloma, in combination with other agents for relapsed or refractory cases.
• Pharmacokinetics: Oral bioavailability, favorable dosing schedule (once weekly).
• Regulatory Status: Approved in the U.S., EU, and other major markets (e.g., Japan, Canada).

---

Market Overview: Size and Growth Potential

Global Multiple Myeloma Market

Parameter	2022 Estimate	2027 Projection	CAGR (2022-2027)	Notes
Market Size	USD 16.2 billion	USD 23.5 billion	8.2%	Based on IQVIA, 2022
Key Drivers	Increased prevalence, aging populations, novel therapies

Ixazomib Market Share and Revenue

• Current Market Share: Approx. 15%–20% within the proteasome inhibitor segment (as of 2022).
• Revenue (2022): Estimated USD 600 million globally.
• Forecasted Revenue (2027): USD 1.2 billion, assuming steady adoption and expanded indications.

Market Penetration Factors

• Oral administration preference
• Favorable safety and tolerability profile
• Competitive landscape with existing proteasome inhibitors (e.g., bortezomib, carfilzomib)

---

Competitive Landscape and Market Dynamics

Major Competitors

Drug Name	Type	Administration	Key Markets	2022 Market Share	Price Point (USD)	Notes
Bortezomib	Injectable proteasome inhibitor	IV/Subcutaneous	Global	55%	USD 70,000/year	First-line and relapsed indications
Carfilzomib	Injectable proteasome inhibitor	IV	Global	20%	USD 105,000/year	Higher toxicity profile
Ixazomib citrate	Oral proteasome inhibitor	Oral	Global	15–20%	USD 25,000/year	Competitive advantage in oral delivery

Market Dynamics Influencing Ixazomib’s Trajectory

• Regulatory Approvals: Expansion into new indications can boost revenue.
• Patient Preference: Oral drugs favored for outpatient management.
• Pricing and Reimbursement: Variability across markets affects adoption.
• Competitive Innovations: Newer agents or biosimilars could erode market share.
• Combination Therapies: Evolving treatment protocols incorporating ixazomib (e.g., with lenalidomide/dexamethasone) potentiate sales.

---

Key Market Drivers and Barriers

Drivers	Barriers
Oral administration enhances compliance	Competition from newer agents with better efficacy
Favorable safety profile	Patent expiration risks
Growing prevalence of multiple myeloma	Regulatory delays and pricing pressures
Expansion into earlier lines of therapy	Cost of development and approval for new indications
Emerging combination regimens	Market saturation in mature segments

---

Financial Trajectory: Projections & Trends

Revenue Forecast (2023–2027)

Year	Estimated Revenue (USD Billions)	Growth Rate	Assumptions
2023	0.75	25%	Initial post-pandemic market stabilization
2024	0.90	20%	Increased adoption, global expansion
2025	1.05	17%	Pipeline developments, new indication filings
2026	1.10	5%	Market saturation, pricing pressures
2027	1.20	9%	Broader use, combination therapy approvals

Profitability Outlook

• Cost of Goods Sold (COGS): Approx. 20–25%
• Research & Development: 15–20%, mainly for new indications
• Pricing Strategies: Tiered, market-specific to optimize margins
• Margins: Projected gross margin of around 70%, net margins expected at 20–25% in mature phases

Investment Summary:

Aspect	Insight	Risks
Market potential	Strong with expanding indications and oral advantage	Patent expiration and generic entry
Competitive positioning	Differentiated via convenience and tolerability	Competition from biosimilars and advanced agents
Regulatory landscape	Generally supportive, with fast-track options	Regulatory delays or setbacks
Financial outlook	Steady growth driven by expansion in indications	Pricing reforms, reimbursement constraints

---

Deep Dive: Comparison with Competitors

Feature/Parameter	Ixazomib citrate	Bortezomib	Carfilzomib
Administration	Oral	Injectable (IV/subQ)	Injectable (IV)
Approved Indications	MM (relapsed/refractory)	MM (multiple lines)	MM (relapsed/refractory)
Market Share (2022)	15–20%	55%	20%
Pricing (approximate/year)	USD 25,000	USD 70,000	USD 105,000
Safety Profile	Favorable	Moderate (peripheral neuropathy)	Higher toxicity potential
Patient Preference	High due to oral form	Lower	Lower

---

Potential Strategic Moves for Investment

• Portfolio Expansion: Partner or acquire rights in emerging indications.
• Pipeline Advancement: Accelerate development for early-line therapy.
• Market Penetration: Increase access in emerging markets.
• Pricing & Reimbursement: Engage with payers for favorable terms.
• Technology Integration: Leverage digital health for adherence monitoring.

---

Regulatory and Policy Frameworks Impacting Market Trajectory

Region	Regulatory Trend	Impact on Ixazomib
United States (FDA)	Priority review pathways, accelerated approval	Expedites access for new indications
European Union (EMA)	Orphan drug designation, conditional approvals	Facilitates market entry and reimbursement
Japan	Strict drug approval processes, high costs	Potential delays, but large market size
Emerging Markets	Evolving regulatory policies	Untapped potential, risks of registration delays

---

Key Challenges and Mitigation Strategies

Challenge	Mitigation Approach
Patent expiration	Obtain new patents, develop next-generation formulations
Pricing pressures	Value-based pricing, differential pricing strategies
Competitive innovations	Invest in pipeline, combination therapies research
Access and reimbursement	Foster payer relationships and demonstrate clinical value

---

Key Takeaways

• Market Growth: The global multiple myeloma treatment market is projected to grow at an 8.2% CAGR, with ixazomib citrate expected to follow a similar trajectory as oral proteasome inhibitors gain prominence.
• Revenue Expansion: Estimated to reach USD 1.2 billion by 2027, driven by broader indication approvals and increased adoption in combination regimens.
• Competitive Position: Maintains a favorable niche owing to oral administration, safety profile, and evolving treatment protocols.
• Risks and Challenges: Patent expiry, biosimilar competition, pricing pressure, and regulatory hurdles could impact profit margins.
• Investment Opportunities: Focus on pipeline development, geographic expansion, and value-based pricing schemes to maximize returns.

---

FAQs

1. What are the key factors that could accelerate ixazomib citrate’s market growth?
   The expansion into earlier lines of therapy, approval for additional indications, and favorable reimbursement policies are primary accelerators.

2. How does ixazomib citrate compare economically with its main competitors?
   It is priced substantially lower (~USD 25,000/year) than injectable counterparts like bortezomib (~USD 70,000/year), providing cost advantages that can enhance adoption, especially in cost-sensitive markets.

3. What are the main regulatory considerations for ixazomib citrate?
   Rapid approval pathways and orphan drug designations facilitate market entry, but new indications require rigorous clinical evidence and could face delays.

4. What are the patent expiry risks for ixazomib citrate?
   Patent protection in major markets is expected to extend into the late 2020s, but biosimilar competition or patent challenges could threaten exclusivity.

5. In which markets does ixazomib citrate have the highest growth potential?
   Emerging markets and regions with increasing healthcare infrastructure, such as Southeast Asia, Latin America, and Africa, offer high growth opportunities.

---

References

[1] IQVIA, 2022. Global Oncology Market Data.
[2] BloombergNEF, 2022. Biopharma Industry Reports.
[3] U.S. FDA. Drug approval documents for ixazomib citrate, 2015.
[4] EMA. Market Authorization summarization for ixazomib citrate, 2016.
[5] GlobalData, 2022. Oncology Therapeutics Market Outlook.